Research Topics
| GREGORY LUCASSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Decreased kidney function in a community-based cohort of HIV-Infected and HIV-negative individuals in Rakai, UgandaGregory M Lucas
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
J Acquir Immune Defic Syndr 55:491-4. 2010..However little is known about natural history HIV-related kidney disease or about background rates of reduced GFR in HIV-negative individuals in this region...- Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058Gregory M Lucas
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Int J Drug Policy 23:162-5. 2012.... - Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programsBernadette Anna Mullen
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
BMC Infect Dis 11:45. 2011..Prior work from our group and others suggests that directly administered antiretroviral therapy (DAART) delivered in opioid treatment programs (OTPs) may increase rates of viral suppression... 
Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is wovenGregory M Lucas
Johns Hopkins University, Baltimore, MD 21287, USA
J Antimicrob Chemother 55:413-6. 2005..Such benefit may be mediated, at least partially, by reductions in viral fitness associated with drug resistance mutations...- Adherence to antiretroviral therapy: an update of current conceptsGregory M Lucas
Johns Hopkins Medical Institutions, 1830 E Monument Street, Room 421, Baltimore, MD 21287, USA
Curr HIV/AIDS Rep 1:172-80. 2004..Owing to the great benefits of CART even the small to modest gains in adherence that are achievable with adherence programs may prove to be cost effective... - Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapyGregory M Lucas
Division of Infectious Diseases, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Am J Epidemiol 163:412-20. 2006..2, 2.8). Active drug use is temporally linked to HIV disease progression and mortality. Effectively targeting and treating active substance abuse in HIV treatment settings may provide a mechanism to improve clinical outcomes... - Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groupsGregory M Lucas
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
Clin Infect Dis 42:1628-35. 2006..Directly administered antiretroviral therapy (DAART) in methadone clinics has the potential to improve treatment outcomes for human immunodeficiency virus (HIV)-infected injection drug users (IDUs)... - Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two racesGregory M Lucas
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicines, Baltimore, Maryland, USA
J Infect Dis 197:1548-57. 2008..Little is known about the racial differences in the incidence and progression of HIV-related chronic kidney disease (CKD) that underlie African American-white disparities in HIV-related end-stage renal disease (ESRD)... - Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapyGregory M Lucas
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
AIDS Patient Care STDS 21:564-74. 2007..Given that a relatively small proportion of the total ART doses were supervised in many patients, future studies should assess how DAART affects adherence with nonsupervised doses and retention to ART... - Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trialGregory M Lucas
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Ann Intern Med 152:704-11. 2010..Opioid dependence is common in HIV clinics. Buprenorphine-naloxone (BUP) is an effective treatment of opioid dependence that may be used in routine medical settings... - Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individualsGregory M Lucas
Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States
Life Sci 88:948-52. 2011..Strategies that show promise for HIV-infected substance abusers include integrated treatment models, directly observed therapy, and incentive-based interventions... - Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testingGregory M Lucas
Johns Hopkins University, Baltimore, Maryland, USA
AIDS 18:1539-48. 2004.... - Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden?Gregory M Lucas
Department of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland 21287 0003, USA
AIDS Patient Care STDS 16:527-35. 2002.... - Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative studyGregory M Lucas
Johns Hopkins University, Baltimore, MD 21287, USA
Clin Infect Dis 38:S409-13. 2004..008). The preliminary results of this study both suggest that DAART can be feasible and acceptable to patients in a methadone clinic setting and provide impetus for further study of this treatment strategy in randomized controlled trials... - Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort studyGregory M Lucas
Johns Hopkins University, Baltilmore, Maryland 21287, USA
J Acquir Immune Defic Syndr 33:321-8. 2003..To examine the implications of early virologic response to highly active antiretroviral therapy (HAART) on long-term HAART utilization patterns, development of diabetes or hyperlipidemia, and mortality in an urban HIV-1 clinic... - Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort studyGregory M Lucas
Johns Hopkins University, Baltimore and the Good Samaritan Hospital, Baltimore, Maryland, USA
AIDS 18:541-6. 2004..to assess temporal changes in the incidence of human immunodeficiency virus-1-associated nephropathy (HIVAN), and the association with use of highly active antiretroviral therapy (HAART)... - Detrimental effects of continued illicit drug use on the treatment of HIV-1 infectionG M Lucas
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Acquir Immune Defic Syndr 27:251-9. 2001..To identify the effects of substance abuse status (active, former, and never) on utilization of highly active antiretroviral therapy (HAART), medication adherence, and virologic and immunologic responses to therapy... - A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohortDavid J Riedel
Institute of Human Virology and Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
AIDS Patient Care STDS 22:113-21. 2008..Of note, newer antiretrovirals, particularly atazanavir, lopinivir/ritonavir, tenofovir, abacavir, and efavirenz, were not associated with an increased risk of pancreatitis... - Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinicGregory M Lucas
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
AIDS 16:767-74. 2002..CONCLUSIONS: This longitudinal study highlights the dynamic nature of substance abuse and its temporal association with the effectiveness of HIV-1 treatment in patients attending an inner-city clinic... - End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004Gregory M Lucas
Department of Medicine, Divisions of Infectious Diseases, Bloomberg School of Public Health, John Hopkins University, Baltimore, Maryland, USA
AIDS 21:2435-43. 2007..HIV-infected African-Americans are at increased risk of end-stage renal disease requiring renal replacement therapy (RRT)... - Characteristics of patients with HIV and biopsy-proven acute interstitial nephritisShyam M Parkhie
Division of Renal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA
Clin J Am Soc Nephrol 5:798-804. 2010..The objective of this study was to describe the characteristics of patients with HIV infection and biopsy-proven acute interstitial nephritis (AIN)... 
HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and managementMohamed G Atta
Expert Rev Anti Infect Ther 6:365-71. 2008..Furthermore, HAART, corticosteroids and inhibition of the renin-angiotensin axis are potentially helpful in delaying disease progression, as well as the need for renal replacement therapy...- Cocaine use and hypertensive renal changes in HIV-infected individualsDerek M Fine
Department of Medicine, Johns Hopkins School of Medicine and the Johns Hopkins Hospital, Baltimore, Maryland, USA
Clin J Am Soc Nephrol 2:1125-30. 2007..This study was conducted to evaluate the possible association of cocaine use and histopathologic findings on biopsy in this population... - Renal disease in patients with HIV infection: epidemiology, pathogenesis and managementDerek M Fine
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Drugs 68:963-80. 2008..Only with greater awareness of kidney-disease manifestations and their implications in this particularly vulnerable population will we be able to achieve success in confronting this growing problem... - Observations on a cohort of HIV-infected patients undergoing native renal biopsyAdam R Berliner
Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Am J Nephrol 28:478-86. 2008..This study aims to explore the spectrum of renal disease in HIV-infected patients, identify clinical predictors of HIV-associated nephropathy (HIVAN), and investigate the performance of renal biopsy in HIV-infected patients... - Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: possible role of hepatitis C and HIV co-infectionSayed Tabatabai
Department of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Clin J Am Soc Nephrol 4:1766-73. 2009..HIV-infected patients often undergo kidney biopsy. The risks of percutaneous ultrasound-guided kidney biopsy in this population are not well established... - Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, MarylandMohamed G Atta
Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Clin Infect Dis 45:1625-32. 2007..It is unknown how the widespread use of highly active antiretroviral therapy (HAART) has affected survival during RRT in this vulnerable population... - Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use statusRichard D Moore
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Clin Infect Dis 47:1102-4. 2008..Among patients with a CD4 cell count <350 cells/mm(3), receipt of HAART was associated with a significantly decreased incidence of comorbidities not related to HIV infection or AIDS... - Antiretroviral nephrotoxicitiesMohamed G Atta
Department of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Semin Nephrol 28:563-75. 2008..A timely and coordinated effort by the HIV primary provider and a nephrologist is likely to facilitate the evaluation of HIV-1-infected patients with new kidney problems... - Nonstructured treatment interruptions among injection drug users in Baltimore, MDRavi Kavasery
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
J Acquir Immune Defic Syndr 50:360-6. 2009..We characterized patterns of highly active antiretroviral therapy (HAART) use and predictors of nonstructured treatment interruptions (NTIs) among injection drug users (IDUs) in Baltimore, MD... - Kidney biopsy in HIV: beyond HIV-associated nephropathyDerek M Fine
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Am J Kidney Dis 51:504-14. 2008 - Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohortKelly A Gebo
Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21205, USA
J Acquir Immune Defic Syndr 43:426-32. 2006..We evaluated the incidence of, risk factors for, clinical presentation, and 1-year outcomes of IE in HIV-infected patients... - Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003Pennan M Barry
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
AIDS 20:437-44. 2006..To investigate the association between the introduction of HAART and invasive pneumococcal disease (IPD) in HIV-infected patients... - An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002Richard D Moore
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
J Acquir Immune Defic Syndr 39:195-8. 2005..This suggests that improved virologic response may also be attributable to other factors such as a greater focus on medication adherence, improved ARV tolerability, and ease of dosing... - Treatment of antiretroviral-experienced patients and immune-based therapyGregory M Lucas
Hopkins HIV Rep 14:7-9. 2002 - HIV notes from the 39th Annual Meeting of the IDSAGregory M Lucas
Hopkins HIV Rep 14:8-10. 2002 - Buprenorphine use: the international experienceMaria Patrizia Carrieri
INSERM U379, Marseilles, France
Clin Infect Dis 43:S197-215. 2006.... - HIV notes from the 40th annual meeting of the Infectious Diseases Society of AmericaEmily J Erbelding
Hopkins HIV Rep 14:6-7. 2002 - Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). The treatment of experienced patients and resistance mechanismsGregory M Lucas
Hopkins HIV Rep 16:6-7, 15. 2004 - Treatment of experienced patients and antiretroviral resistance issues from the 12th CROIGregory M Lucas
Hopkins HIV Rep 17:1-3, 12. 2005 - Initial strategies for integrating buprenorphine into HIV care settings in the United StatesLynn E Sullivan
Yale University School of Medicine, New Haven, CT 06520 8025, USA
Clin Infect Dis 43:S191-6. 2006.... - Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinicShruti H Mehta
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA
AIDS 20:2361-9. 2006..New therapies and treatment strategies are an urgent medical need... - Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST)Bruno Spire
INSERM U379 ORSPACA, Marseilles, France
Int J Drug Policy 18:262-70. 2007..The review concludes by suggesting areas of future research targeted at improving the understanding of both the role of perceived toxicity and patient-provider relationship for patients on ART and OST... - Selected topics from the 9th Conference on Retroviruses and Opportunistic InfectionsRichard E Chaisson
HIV Clin Trials 3:333-49. 2002 - Report from Los Angeles: the 14th Conference on Retroviruses and Opportunistic Infections (CROI). New data on treatment-experienced patients and drug resistanceGregory M Lucas
Hopkins HIV Rep 19:4-6. 2007 - 3rd IAS conference: new drugs and treatment of experienced patientsGregory M Lucas
Hopkins HIV Rep 17:4-5. 2005 - Antiretroviral toxicities take center stage at the 9th CROI (Conference on Retroviruses and Opportunistic Infections)Gregory M Lucas
Hopkins HIV Rep 14:1, 4, 9. 2002 - Taking HAART to heart: antiretroviral toxicitiesGregory M Lucas
Hopkins HIV Rep 15:6-7. 2003 - Buprenorphine in primary HIV care clinics: a big pill to swallowGregory M Lucas
Hopkins HIV Rep 16:5-7. 2004 - Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patientsMark J Siedner
J Acquir Immune Defic Syndr 47:261-3. 2008
Research Grants
- Directly observed antiretroviral therapy in drug abusersGREGORY LUCAS; Fiscal Year: 2006..My career plan and research proposal are consistent with my long-term goals of becoming an effective independent investigator, and optimizing treatment outcomes in HIV-infected IDUs. ..
- Directly Administered HIV Therapy in Methadone ClinicsGREGORY LUCAS; Fiscal Year: 2009..Our research team has an established history of collaboration in this area, and brings together a wealth of research expertise in HIV treatment outcomes, substance abuse, and behavioral aspects of adherence. ..
- Early-Stage Chronic Kidney Disease in HIV-infected IndividualsGregory M Lucas; Fiscal Year: 2010..In a sample of HIV-infected and HIV- negative research participants, we propose to study clinical markers and contributing factors in the progression of kidney disease, and the association between kidney disease and heart disease. ..